Histone Deacetylase Inhibitors

"Histone Deacetylase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains.

Descriptor ID	D056572
MeSH Number(s)	D27.505.519.389.360
Concept/Terms	Histone Deacetylase Inhibitors Histone Deacetylase Inhibitors Deacetylase Inhibitors, Histone Inhibitors, Histone Deacetylase Histone Deacetylase Inhibitor Deacetylase Inhibitor, Histone Inhibitor, Histone Deacetylase HDAC Inhibitors Inhibitors, HDAC

Below are MeSH descriptors whose meaning is more general than "Histone Deacetylase Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Histone Deacetylase Inhibitors [D27.505.519.389.360]

Below are MeSH descriptors whose meaning is related to "Histone Deacetylase Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Histone Deacetylase Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Histone Deacetylase Inhibitors" by people in this website by year, and whether "Histone Deacetylase Inhibitors" was a major or minor topic of these publications.

Bar chart showing 31 publications over 14 distinct years, with a maximum of 7 publications in 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2003	0	1	1
2007	1	1	2
2010	3	0	3
2011	2	1	3
2013	0	3	3
2015	4	3	7
2016	1	0	1
2017	1	0	1
2018	1	0	1
2019	1	1	2
2020	3	1	4
2022	0	1	1
2024	1	0	1
2025	1	0	1

Below are the most recent publications written about "Histone Deacetylase Inhibitors" by people in Profiles.

Ndukwe K, Serrano PA, Rockwell P, Xie L, Figueiredo-Pereira ME. Brain-penetrant histone deacetylase inhibitor RG2833 improves spatial memory in females of an Alzheimer's disease rat model. J Alzheimers Dis. 2025 Mar; 104(1):173-190.

View in: PubMed
Bornes KE, Moody MA, Huckaba TM, Benz MC, McConnell EC, Foroozesh M, Barnes VH, Collins-Burow BM, Burow ME, Watt TJ, Toro TB. Lysine deacetylase inhibitors have low selectivity in cells and exhibit predominantly off-target effects. FEBS Open Bio. 2025 Jan; 15(1):94-107.

View in: PubMed
Wei H, Gou W, Gao J, Ning H, Song Y, Li D, Qin Y, Hou W, Li Y. Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury. Eur J Med Chem. 2022 Feb 15; 230:114115.

View in: PubMed
Ranganna K, Selvam C, Shivachar A, Yousefipour Z. Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach. Int J Mol Sci. 2020 Nov 02; 21(21).

View in: PubMed
Shah SG, Mandloi T, Kunte P, Natu A, Rashid M, Reddy D, Gadewal N, Gupta S. HISTome2: a database of histone proteins, modifiers for multiple organisms and epidrugs. Epigenetics Chromatin. 2020 08 03; 13(1):31.

View in: PubMed
Upadhyay N, Tilekar K, J?nsch N, Schweipert M, Hess JD, Henze Macias L, Mrowka P, Aguilera RJ, Choe JY, Meyer-Almes FJ, Ramaa CS. Discovery of novel N-substituted thiazolidinediones (TZDs) as HDAC8 inhibitors: in-silico studies, synthesis, and biological evaluation. Bioorg Chem. 2020 07; 100:103934.

View in: PubMed
Amnekar RV, Khan SA, Rashid M, Khade B, Thorat R, Gera P, Shrikhande SV, Smoot DT, Ashktorab H, Gupta S. Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer. World J Gastroenterol. 2020 Feb 14; 26(6):598-613.

View in: PubMed
Zhang JH, Mottamal M, Jin HS, Guo S, Gu Y, Wang G, Zhao LM. Design, synthesis and evaluation of belinostat analogs as histone deacetylase inhibitors. Future Med Chem. 2019 11; 11(21):2765-2778.

View in: PubMed
Eto S, Saeki K, Yoshitake R, Yoshimoto S, Shinada M, Ikeda N, Kamoto S, Tanaka Y, Kato D, Maeda S, Tsuboi M, Chambers J, Uchida K, Nishimura R, Nakagawa T. Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells. PLoS One. 2019; 14(6):e0218382.

View in: PubMed
Mazzio EA, Soliman KFA. Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A. Cancer Genomics Proteomics. 2018 Sep-Oct; 15(5):349-364.

View in: PubMed

People

Explore

Similar Concepts

Top Journals